Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations PRESS RELEASE Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations Emergex confirms that...

Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine PRESS RELEASE Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine Swiss regulatory authorities, including the Swiss Agency for Therapeutic...

Midatech Signs Licensing Agreement With Emergex Vaccines CAMBRIDGE, United Kingdom, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Midatech Pharma (AIM:MTPH) (Nasdaq:MTP), the international specialty pharmaceutical company focused on developing and commercialising...